Expression of RPLP0 in glioma - The Human Protein Atlas

GLIOBLASTOMA MULTIFORME (TCGA) - Interactive survival scatter plotⁱ

The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.

The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".

Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.

Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.

& Survival analysisⁱ

RPLP0 is not prognostic in Glioblastoma Multiforme (TCGA)

Stage:

Survival analysis

Current cut offⁱ :

Best expression cut offⁱ : 2554.07

Median expressionⁱ : N/A

Median follow up timeⁱ : N/A

P scoreⁱ N/A

3-year survival highⁱ N/A

3-year survival lowⁱ N/A

RNA samplesⁱ

Average pTPM

2845.6

Number of samples

141

Samples

Sample	Description	pTPM
TCGA-27-2521-01A	34 years, male, white, stage:'--, dead, 510 days	8792.8
TCGA-14-0871-01A	74 years, female, white, stage:'--, dead, 880 days	5898.1
TCGA-28-5218-01A	63 years, male, white, stage:'--, dead, 157 days	5812.4
TCGA-32-5222-01A	66 years, male, white, stage:'--, dead, 585 days	5086.0
TCGA-26-5133-01A	59 years, male, white, stage:'--, alive, 452 days	5006.9
TCGA-06-0178-01A	38 years, male, white, stage:'--, dead, 2681 days	4851.2
TCGA-12-3652-01A	60 years, male, white, stage:'--, dead, 1062 days	4810.4
TCGA-14-1823-01A	58 years, female, white, stage:'--, dead, 543 days	4611.4
TCGA-06-5417-01A	45 years, female, white, stage:'--, alive, 155 days	4603.3
TCGA-06-2569-01A	24 years, female, black or african american, stage:'--, alive, 13 days	4553.3
TCGA-12-5295-01A	60 years, female, white, stage:'--, dead, 454 days	4526.4
TCGA-14-2554-01A	52 years, female, white, stage:'--, dead, 532 days	4481.4
TCGA-02-2483-01A	43 years, male, asian, stage:'--, alive, 466 days	4425.7
TCGA-12-5299-01A	56 years, female, white, stage:'--, dead, 98 days	4385.2
TCGA-27-2524-01A	56 years, male, white, stage:'--, dead, 231 days	4384.5
TCGA-06-0744-01A	66 years, male, white, stage:'--, dead, 1426 days	4368.4
TCGA-06-5418-01A	75 years, female, white, stage:'--, dead, 83 days	4157.4
TCGA-28-2513-01A	69 years, female, white, stage:'--, alive, 222 days	4151.7
TCGA-41-5651-01A	59 years, female, black or african american, stage:'--, dead, 460 days	4104.3
TCGA-28-2509-01A	77 years, female, white, stage:'--, alive, 145 days	3914.7
TCGA-06-0211-01A	47 years, male, white, stage:'--, dead, 360 days	3893.6
TCGA-41-2571-01A	89 years, male, white, stage:'--, dead, 26 days	3802.8
TCGA-06-0174-01A	54 years, male, white, stage:'--, dead, 98 days	3799.3
TCGA-14-0817-01A	69 years, female, white, stage:'--, dead, 164 days	3718.7
TCGA-12-3650-01A	46 years, male, white, stage:'--, dead, 333 days	3712.2
TCGA-02-0055-01A	62 years, female, white, stage:'--, dead, 76 days	3709.0
TCGA-32-4213-01A	47 years, female, white, stage:'--, alive, 604 days	3617.3
TCGA-06-2570-01A	21 years, female, white, stage:'--, alive, 958 days	3601.9
TCGA-06-5416-01A	23 years, female, white, stage:'--, alive, 204 days	3599.4
TCGA-12-0616-01A	36 years, female, white, stage:'--, dead, 448 days	3549.0
TCGA-76-4925-01A	76 years, male, white, stage:'--, dead, 146 days	3544.0
TCGA-27-2528-01A	62 years, male, white, stage:'--, dead, 480 days	3467.8
TCGA-76-4932-01A	50 years, female, white, stage:'--, dead, 1458 days	3405.1
TCGA-06-2563-01A	72 years, female, white, stage:'--, alive, 932 days	3393.5
TCGA-19-5960-01A	56 years, male, white, stage:'--, dead, 455 days	3336.2
TCGA-28-5208-01A	52 years, male, white, stage:'--, dead, 544 days	3310.0
TCGA-06-0686-01A	53 years, male, white, stage:'--, dead, 432 days	3267.2
TCGA-06-0156-01A	57 years, male, white, stage:'--, dead, 178 days	3236.7
TCGA-02-2485-01A	53 years, male, black or african american, stage:'--, alive, 470 days	3219.2
TCGA-27-1831-01A	66 years, male, white, stage:'--, dead, 505 days	3189.3
TCGA-28-5209-01A	66 years, female, white, stage:'--, alive, 442 days	3179.9
TCGA-14-1825-01A	70 years, male, white, stage:'--, dead, 232 days	3177.6
TCGA-41-2572-01A	67 years, male, white, stage:'--, dead, 406 days	3111.4
TCGA-14-1829-01A	57 years, male, black or african american, stage:'--, alive, 218 days	3104.9
TCGA-12-3653-01A	34 years, female, white, stage:'--, dead, 442 days	3104.4
TCGA-76-4927-01A	58 years, male, white, stage:'--, dead, 535 days	3104.1
TCGA-76-4931-01A	70 years, female, white, stage:'--, dead, 279 days	3091.0
TCGA-28-5204-01A	72 years, male, white, stage:'--, dead, 454 days	3089.7
TCGA-06-0745-01A	59 years, male, white, stage:'--, dead, 239 days	3047.9
TCGA-06-0130-01A	54 years, male, white, stage:'--, dead, 394 days	3037.1
TCGA-27-2526-01A	79 years, female, white, stage:'--, dead, 87 days	3005.9
TCGA-06-0645-01A	55 years, female, white, stage:'--, dead, 175 days	3003.5
TCGA-14-0787-01A	69 years, male, asian, stage:'--, dead, 68 days	2984.0
TCGA-14-0789-01A	54 years, male, white, stage:'--, dead, 342 days	2957.1
TCGA-02-2486-01A	64 years, male, white, stage:'--, dead, 618 days	2932.1
TCGA-06-0138-01A	43 years, male, white, stage:'--, dead, 737 days	2918.5
TCGA-26-5132-01A	74 years, male, white, stage:'--, alive, 286 days	2917.0
TCGA-41-3915-01A	48 years, male, white, stage:'--, dead, 360 days	2905.7
TCGA-32-2638-01A	67 years, male, white, stage:'--, dead, 766 days	2876.0
TCGA-15-0742-01A	65 years, male, white, stage:'--, dead, 419 days	2857.3
TCGA-19-4065-01A	36 years, male, white, stage:'--, alive, 214 days	2857.2
TCGA-06-0168-01A	59 years, female, white, stage:'--, dead, 598 days	2848.1
TCGA-06-0644-01A	71 years, male, black or african american, stage:'--, dead, 384 days	2846.7
TCGA-26-1442-01A	43 years, male, white, stage:'--, alive, 953 days	2811.7
TCGA-06-5414-01A	61 years, male, white, stage:'--, alive, 273 days	2800.5
TCGA-06-5413-01A	67 years, male, white, stage:'--, alive, 268 days	2778.5
TCGA-27-2523-01A	63 years, male, white, stage:'--, dead, 489 days	2777.6
TCGA-32-2634-01A	82 years, male, white, stage:'--, alive, 693 days	2770.6
TCGA-06-0238-01A	46 years, male, white, stage:'--, dead, 405 days	2675.1
TCGA-14-1034-01A	60 years, female, stage:'--, dead, 485 days	2663.7
TCGA-06-0190-01A	62 years, male, white, stage:'--, dead, 317 days	2650.0
TCGA-06-5408-01A	54 years, female, white, stage:'--, dead, 357 days	2644.4
TCGA-32-2615-01A	62 years, male, white, stage:'--, dead, 485 days	2612.0
TCGA-12-0821-01A	62 years, male, white, stage:'--, dead, 323 days	2596.5
TCGA-28-5216-01A	52 years, male, white, stage:'--, alive, 415 days	2580.1
TCGA-06-0125-01A	63 years, female, white, stage:'--, dead, 1448 days	2556.3
TCGA-27-1832-01A	59 years, female, white, stage:'--, dead, 300 days	2551.8
TCGA-06-2565-01A	59 years, male, asian, stage:'--, dead, 506 days	2514.9
TCGA-26-5135-01A	72 years, female, white, stage:'--, dead, 270 days	2489.3
TCGA-06-0210-01A	72 years, female, white, stage:'--, dead, 225 days	2452.9
TCGA-12-0618-01A	49 years, male, white, stage:'--, dead, 395 days	2426.7
TCGA-32-2632-01A	80 years, male, white, stage:'--, dead, 269 days	2422.3
TCGA-19-2629-01A	60 years, male, white, stage:'--, dead, 737 days	2404.7
TCGA-06-0129-01A	30 years, male, asian, stage:'--, dead, 1024 days	2387.3
TCGA-32-1982-01A	76 years, female, white, stage:'--, dead, 142 days	2358.9
TCGA-19-2625-01A	76 years, female, white, stage:'--, dead, 124 days	2356.8
TCGA-06-5410-01A	72 years, female, white, stage:'--, dead, 108 days	2336.2
TCGA-06-0219-01A	67 years, male, white, stage:'--, dead, 22 days	2324.6
TCGA-26-5139-01A	65 years, female, white, stage:'--, alive, 48 days	2321.2
TCGA-32-2616-01A	48 years, female, white, stage:'--, dead, 224 days	2318.8
TCGA-06-0139-01A	40 years, male, white, stage:'--, dead, 362 days	2308.0
TCGA-06-5412-01A	78 years, female, white, stage:'--, dead, 138 days	2299.7
TCGA-27-1830-01A	57 years, male, white, stage:'--, dead, 154 days	2277.0
TCGA-06-0747-01A	53 years, male, white, stage:'--, dead, 82 days	2259.8
TCGA-06-5858-01A	45 years, female, white, stage:'--, alive, 187 days	2234.2
TCGA-06-2558-01A	75 years, female, white, stage:'--, dead, 380 days	2231.4
TCGA-28-5215-01A	62 years, female, white, stage:'--, dead, 335 days	2230.0
TCGA-27-1837-01A	36 years, male, white, stage:'--, dead, 427 days	2188.4
TCGA-19-1390-01A	63 years, female, white, stage:'--, dead, 772 days	2155.0
TCGA-06-2559-01A	83 years, male, white, stage:'--, dead, 150 days	2143.2
TCGA-06-0158-01A	73 years, male, white, stage:'--, dead, 329 days	2137.5
TCGA-19-2619-01A	55 years, female, black or african american, stage:'--, alive, 294 days	2114.9
TCGA-27-1835-01A	53 years, female, white, stage:'--, dead, 648 days	2113.2
TCGA-26-5134-01A	74 years, male, white, stage:'--, alive, 167 days	2096.0
TCGA-28-1753-01A	53 years, male, white, stage:'--, alive, 37 days	2058.2
TCGA-06-0882-01A	30 years, male, white, stage:'--, dead, 632 days	2052.1
TCGA-16-0846-01A	85 years, male, white, stage:'--, dead, 119 days	2029.2
TCGA-28-5220-01A	67 years, male, white, stage:'--, dead, 388 days	2019.8
TCGA-06-2564-01A	50 years, male, white, stage:'--, alive, 181 days	2006.6
TCGA-28-2514-01A	45 years, male, asian, stage:'--, alive, 160 days	2005.3
TCGA-19-2624-01A	51 years, male, white, stage:'--, dead, 5 days	2000.7
TCGA-06-0878-01A	74 years, male, white, stage:'--, alive, 218 days	1974.0
TCGA-32-1970-01A	59 years, male, white, stage:'--, dead, 468 days	1970.0
TCGA-06-2567-01A	65 years, male, white, stage:'--, dead, 133 days	1942.3
TCGA-28-5207-01A	71 years, male, white, stage:'--, dead, 343 days	1942.0
TCGA-08-0386-01A	74 years, male, white, stage:'--, dead, 548 days	1934.6
TCGA-06-2562-01A	81 years, male, white, stage:'--, dead, 382 days	1930.4
TCGA-06-2557-01A	76 years, male, black or african american, stage:'--, dead, 33 days	1866.8
TCGA-06-0743-01A	69 years, male, white, stage:'--, dead, 803 days	1862.1
TCGA-06-5411-01A	51 years, male, white, stage:'--, dead, 254 days	1861.9
TCGA-06-0132-01A	49 years, male, white, stage:'--, dead, 771 days	1812.7
TCGA-02-0047-01A	78 years, male, white, stage:'--, dead, 448 days	1804.8
TCGA-06-0157-01A	63 years, female, white, stage:'--, dead, 97 days	1795.9
TCGA-06-0187-01A	69 years, male, white, stage:'--, dead, 828 days	1783.8
TCGA-06-0646-01A	60 years, male, white, stage:'--, dead, 175 days	1777.8
TCGA-32-1980-01A	72 years, male, white, stage:'--, dead, 36 days	1774.3
TCGA-19-2620-01A	70 years, male, white, stage:'--, dead, 148 days	1770.8
TCGA-06-5856-01A	58 years, male, white, stage:'--, dead, 114 days	1762.2
TCGA-06-0184-01A	63 years, male, white, stage:'--, dead, 2126 days	1742.2
TCGA-27-2519-01A	48 years, male, white, stage:'--, dead, 550 days	1738.7
TCGA-06-2561-01A	53 years, female, white, stage:'--, dead, 537 days	1730.7
TCGA-06-0750-01A	43 years, male, white, stage:'--, dead, 28 days	1725.1
TCGA-06-0749-01A	50 years, male, black or african american, stage:'--, dead, 82 days	1678.6
TCGA-76-4929-01A	76 years, female, white, stage:'--, dead, 111 days	1627.7
TCGA-27-1834-01A	56 years, male, white, stage:'--, dead, 1233 days	1571.4
TCGA-12-0619-01A	60 years, male, white, stage:'--, dead, 1062 days	1516.6
TCGA-41-4097-01A	63 years, female, white, stage:'--, dead, 6 days	1516.0
TCGA-15-1444-01A	21 years, male, white, stage:'--, dead, 1537 days	1447.6
TCGA-06-0141-01A	62 years, male, white, stage:'--, dead, 313 days	1308.3
TCGA-06-5859-01A	63 years, male, white, stage:'--, alive, 139 days	1288.3
TCGA-06-1804-01A	81 years, female, white, stage:'--, dead, 414 days	978.5
Show allShow less

GLIOBLASTOMA MULTIFORME (VALIDATION) - Interactive survival scatter plotⁱ

& Survival analysisⁱ

RPLP0 is not prognostic in Glioblastoma Multiforme (validation)

Stage:

Survival analysis

Current cut offⁱ :

Best expression cut offⁱ : 535.81

Median expressionⁱ : N/A

Median follow up timeⁱ : N/A

P scoreⁱ N/A

3-year survival highⁱ N/A

3-year survival lowⁱ N/A

RNA samplesⁱ

Average pTPM

877.5

Number of samples

Samples

Sample	Description	pTPM
AK139	N, NA, stage:NA, dead, 270 days	2027.2
AK066	N, NA, stage:NA, alive, 960 days	2010.4
AK124	N, NA, stage:NA, alive, 1920 days	1737.2
AK072	N, NA, stage:NA, dead, 150 days	1506.4
AK213	N, NA, stage:NA, alive, 2010 days	1404.4
AK055	N, NA, stage:NA, dead, 240 days	1337.1
AK043	N, NA, stage:NA, alive, 660 days	1330.9
AK142	N, NA, stage:NA, alive, 90 days	1319.1
AK236	N, NA, stage:NA, dead, 360 days	1308.0
AK185	N, NA, stage:NA, alive, 330 days	1250.4
AK165	N, NA, stage:NA, alive, 360 days	1237.6
AK098	N, NA, stage:NA, dead, 660 days	1210.0
AK049	N, NA, stage:NA, dead, 180 days	1200.8
AK133	N, NA, stage:NA, dead, 360 days	1179.1
AK074	N, NA, stage:NA, alive, 300 days	1172.4
AK051	N, NA, stage:NA, dead, 360 days	1164.5
AK068	N, NA, stage:NA, alive, 360 days	1128.2
AK188	N, NA, stage:NA, alive, 420 days	1097.3
AK088	N, NA, stage:NA, dead, 360 days	1073.0
AK156	N, NA, stage:NA, dead, 330 days	1064.2
AK178	N, NA, stage:NA, dead, 240 days	1007.9
AK231	N, NA, stage:NA, dead, 240 days	992.9
AK195	N, NA, stage:NA, dead, 390 days	987.4
AK153	N, NA, stage:NA, dead, 240 days	920.3
AK002	N, NA, stage:NA, dead, 570 days	910.6
AK071	N, NA, stage:NA, dead, 540 days	907.3
AK183	N, NA, stage:NA, alive, 360 days	882.3
AK149	N, NA, stage:NA, dead, 420 days	856.0
AK199	N, NA, stage:NA, alive, 1860 days	854.1
AK227	N, NA, stage:NA, alive, 300 days	848.4
AK053	N, NA, stage:NA, dead, 300 days	794.7
AK091	N, NA, stage:NA, dead, 210 days	770.6
AK173	N, NA, stage:NA, dead, 180 days	757.6
AK216	N, NA, stage:NA, dead, 360 days	729.6
AK100	N, NA, stage:NA, alive, 960 days	720.5
AK089	N, NA, stage:NA, dead, 330 days	714.2
AK076	N, NA, stage:NA, alive, 660 days	619.9
AK158	N, NA, stage:NA, dead, 360 days	617.6
AK003	N, NA, stage:NA, dead, 600 days	614.3
AK041	N, NA, stage:NA, alive, 810 days	611.9
AK102	N, NA, stage:NA, alive, 1740 days	611.8
AK103	N, NA, stage:NA, alive, 1320 days	545.0
AK123	N, NA, stage:NA, dead, 180 days	526.7
AK167	N, NA, stage:NA, dead, 180 days	519.0
AK035	N, NA, stage:NA, dead, 210 days	509.5
AK030	N, NA, stage:NA, dead, 120 days	504.8
AK015	N, NA, stage:NA, alive, 720 days	492.5
AK134	N, NA, stage:NA, dead, 360 days	478.2
AK085	N, NA, stage:NA, alive, 660 days	471.1
AK117	N, NA, stage:NA, dead, 210 days	469.6
AK079	N, NA, stage:NA, dead, 210 days	445.3
AK218	N, NA, stage:NA, dead, 180 days	445.1
AK081	N, NA, stage:NA, dead, 180 days	401.5
AK226	N, NA, stage:NA, dead, 360 days	370.4
AK205	N, NA, stage:NA, dead, 120 days	368.6
AK099	N, NA, stage:NA, dead, 420 days	301.4
AK005	N, NA, stage:NA, dead, 240 days	291.6
AK006	N, NA, stage:NA, dead, 360 days	269.8
Show allShow less

GLIOBLASTOMA MULTIFORME - Protein relative expression (CPTAC)

Number of samples

110

Samples

Sample ID	Sample type	nRPX
CPT0206230003	Tumor	1.0
CPT0217000004	Tumor	1.0
CPT0206560003	Tumor	0.8
CPT0219080004	Tumor	0.6
CPT0206110003	Tumor	0.6
CPT0078580003	Tumor	0.6
CPT0168380003	Tumor	0.6
CPT0162020003	Tumor	0.5
CPT0205450004	Tumor	0.5
CPT0189460003	Tumor	0.5
CPT0162100003	Tumor	0.5
CPT0127480003	Tumor	0.5
CPT0087950003	Tumor	0.5
CPT0205570003	Tumor	0.4
CPT0205780003	Tumor	0.4
CPT0218690004	Tumor	0.4
CPT0221180003	Tumor	0.4
CPT0087570003	Tumor	0.3
CPT0093360003	Tumor	0.3
CPT0089150003	Tumor	0.3
CPT0206780003	Tumor	0.3
CPT0217060003	Tumor	0.3
CPT0228220003	Tumor	0.3
CPT0087730003	Tumor	0.3
CPT0123530003	Tumor	0.3
CPT0218330004	Tumor	0.2
CPT0189650004	Tumor	0.2
CPT0206880003	Tumor	0.2
CPT0127420003	Tumor	0.2
CPT0167640003	Tumor	0.2
CPT0125570003	Tumor	0.2
CPT0217710008	Tumor	0.2
CPT0190360004	Tumor	0.2
CPT0168830003	Tumor	0.2
CPT0218830004	Tumor	0.1
CPT0064650003	Tumor	0.1
CPT0002410011	Tumor	0.1
CPT0161730003	Tumor	0.1
CPT0206670004	Tumor	0.1
CPT0167970003	Tumor	0.1
CPT0186100003	Tumor	0.1
CPT0217100003	Tumor	0.1
CPT0087680003	Tumor	0.1
CPT0217880003	Tumor	0.1
CPT0093510003	Tumor	0.1
CPT0093550003	Tumor	0.1
CPT0224540004	Tumor	0.1
CPT0189850004	Tumor	0.1
CPT0206000004	Tumor	0.1
CPT0167530003	Tumor	0.0
CPT0168590003	Tumor	0.0
CPT0071100003	Tumor	0.0
CPT0093590003	Tumor	0.0
CPT0168080003	Tumor	0.0
CPT0175060003	Tumor	0.0
CPT0217190003	Tumor	0.0
CPT0225760003	Tumor	0.0
CPT0064890003	Tumor	0.0
CPT0217430008	Tumor	0.0
CPT0216920008	Tumor	0.0
CPT0182500003	Tumor	0.0
CPT0168480003	Tumor	0.0
CPT0125220003	Tumor	0.0
CPT0224390004	Tumor	-0.1
CPT0189750004	Tumor	-0.1
CPT0182550003	Tumor	-0.1
CPT0079790003	Tumor	-0.1
CPT0093450003	Tumor	-0.1
CPT0218770003	Tumor	-0.1
CPT0206450003	Tumor	-0.1
CPT0182580003	Tumor	-0.1
CPT0199770003	Tumor	-0.1
CPT0218890004	Tumor	-0.1
CPT0168270003	Tumor	-0.1
CPT0225730003	Tumor	-0.2
CPT0104330003	Tumor	-0.2
CPT0196850003	Tumor	-0.2
CPT0207090003	Tumor	-0.2
CPT0167860004	Tumor	-0.2
CPT0162140003	Tumor	-0.2
CPT0092440003	Tumor	-0.2
CPT0189250003	Tumor	-0.2
CPT0207030003	Tumor	-0.2
CPT0168720003	Tumor	-0.2
CPT0224600003	Tumor	-0.2
CPT0218960004	Tumor	-0.2
CPT0205670004	Tumor	-0.2
CPT0208980003	Tumor	-0.2
CPT0201710003	Tumor	-0.2
CPT0209440003	Tumor	-0.3
CPT0125510003	Tumor	-0.3
CPT0205890003	Tumor	-0.3
CPT0189570004	Tumor	-0.3
CPT0206330003	Tumor	-0.3
CPT0167750004	Tumor	-0.3
CPT0204360003	Non-tumor	-0.3
CPT0171580008	Tumor	-0.3
CPT0218670003	Tumor	-0.4
CPT0204400003	Non-tumor	-0.4
CPT0204350003	Non-tumor	-0.4
CPT0104220003	Tumor	-0.5
CPT0224330003	Tumor	-0.5
CPT0204370003	Non-tumor	-0.5
CPT0204390003	Non-tumor	-0.6
CPT0204330003	Non-tumor	-0.6
CPT0190240004	Tumor	-0.6
CPT0204380003	Non-tumor	-0.6
CPT0204340003	Non-tumor	-0.6
CPT0204410003	Non-tumor	-0.7
CPT0204420003	Non-tumor	-0.7
Show allShow less

GLIOMA - Cancer proteome, tumor vs adjacent non-tumor (ProteinTalks DB, GBM)

Number of samples

16 (8 tumor / adjacent non-tumor pairs)

Detected in

8/8 tumors, 8/8 non-tumors

Tumor vs non-tumor

Not significant (log2FC 0.64, adj. p-value 7.13e-2)
Few samples; differential results are less reliable

Samples

Patient ID	Tumor	Non-tumor
GBM_07	15.9	14.4
GBM_01	15.7	15.3
GBM_05	15.4	14.4
GBM_02	15.2	14.2
GBM_08	14.9	14.4
GBM_06	14.8	14.5
GBM_04	14.8	14.4
GBM_03	14.6	14.6

GLIOMA - Protein stainingⁱ A mouse-over function shows sample information and annotation data. Click on an image to view it in a full screen mode. Samples can be filtered based on level of antibody staining by selecting one or several of the following categories: high, medium, low and not detected. The assay and annotation is described here. Note that samples used for immunohistochemistry by the Human Protein Atlas do not correspond to samples in the TCGA dataset.

Antibody stainingⁱ Antibody staining in the annotated cell types in the current human tissue is reported as not detected, low, medium, or high, based on conventional immunohistochemistry profiling in selected tissues. This score is based on the combination of the staining intensity and fraction of stained cells. Each image is clickable and will lead to virtual microscopy that enables deeper exploration of all samples and also displays staining intensity scores, fraction scores and subcellular localization as well as patient and tissue information for each sample. Ascending and descending describe two types of gradient, based on difference in staining intensity between enterocytes in crypts and apical enterocytes. Ascending - the staining intensity is stronger in apical enterocytes (towards the lumen) compared to enterocytes in the crypts (gland based) Descending - the staining is weaker in apical enterocytes compared to enterocytes in crypts	Antibody HPA003512	Antibody HPA073501
Staining
High
Medium
Low
Not detected
Intensity
Strong
Moderate
Weak
Negative
Quantity
>75%
75%-25%
<25%
None
Location
Nuclear
Cytoplasmic/membranous
Cytoplasmic/membranous,nuclear
None
Glioma, malignant, High grade
Glioma, malignant, Low grade
Glioma, malignant, NOS